30 results about "HSF1" patented technology

In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.

The invention discloses a recombinant pichia pastoris genetically engineered bacterium as well as a construction method and application thereof. The pichia pastoris genetically engineered bacterium is constructed by over-expressing a transcription inhibition factor and an activating factor HSF1 in pichia pastoris. The construction method comprises the following steps: (1) carrying out PCR (Polymerase Chain Reaction) amplification on a pichia pastoris genome to obtain an HSF1 gene segment; (2) cloning the HSF1 gene segment to an expression plasmid to obtain a recombinant plasmid; and (3) introducing the linearized recombinant plasmid into pichia pastoris, and screening to obtain the pichia pastoris genetically engineered bacterium. The pichia pastoris genetically engineered bacterium can effectively improve the biofilm forming ability of the pichia pastoris, so that the enzyme activity of the recombinant pichia pastoris under a single immobilized fermentation condition is improved by 28.3% compared with that of a free fermentation starting bacterium, and the fermentation period is shortened by 36.6%. The recombinant bacteria can be stably and continuously subjected to at least seven batches of immobilized fermentation enzyme production, and after seven batches of immobilized fermentation, the enzyme activity of the fermentation enzyme production of the recombinant bacteria is about 7 times higher than that of starting bacteria.

The invention discloses an application of a heat shock transcription factor 1 in regulating expression of a 15kDa selenoprotein. The application provided by the invention is specifically any one of the applications of the heat shock transcription factor 1: (a1) promoting expression of a Sep15 protein in a target cell; (a2) promoting transcription of a Sep15 gene; and (a3) enhancing the activity of a Sep15 promoter in the target cell. According to the application disclosed by the invention, a transcription factor HSF1 can be combined with the Sep15 promoter to adjust transcription of the Sep15 gene and accelerate expression of the Sep15 protein. Under a heat shock and fever of a physiological status, the transcription factor HSF1 can start transcription of Sep15 and improve expression of Sep 15 so as to participate the physiological process and help the protein being corrected folded or help the protein being unfolded and delivered to other proteins to help the proteins to be folded correctly. Under endoplasmic reticulum stress, the HSF1 also can promote expression of Sep 15 to participate protein quality control of endoplasmic reticulum so as to further promote cell survival. The application disclosed by the invention is of important significance in preventing and/or treating endoplasmic reticulum stress related diseases.

The present invention belongs to the biotechnological field and relates to a human myocardial protection gene heat shock transcription factor (HSF1) and a sieving method and a purpose thereof. The present invention adopts the method of ''death trap'' that the gene which resists myocardial cell death is sieved from human cardiac gene, and the human myocardial protection gene heat shock transcription factor 1 is cloned from the obtained gene. The result of transfection cell and animal experiment shows that the obtained human myocardial protection gene has the function of resisting cell death and also has the function of resisting ischemia, protecting myocardial cell and preventing and remedying the heart failure occurrence and development inside the heart of a living organism. The present invention can prepare for the medicine for remedying the ischemic heart disease and preventing the cardiac insufficiency and provides a novel target gene for the further function research and the gene engineering medicine development, which has important meaning for the early prevention and treatment of the heart failure and the research and the development of the related medicines and measures.

The invention provides a molecular marker HSF1 for diagnosing and treating bladder cancer and an application thereof. Comparison of gene expression results in a bladder cancer clinical specimen shows that HSF1 is highly expressed in bladder cancer tissue with positive lymphatic metastasis, and negatively correlated with overall survival prognosis. The molecular marker can be used as a marker to indicate lymphatic metastasis in bladder cancer, and as an independent indicator to predict survival prognosis of a patient. In-vivo and in-vitro function experiments of bladder cancer cells show the silencing HSF1 can inhibit proliferation of bladder cancer cells and lymphatic metastasis. The invention discovers that HSF1 is an important carcinogenic factor of bladder cancer for the first time, and the HSF1 can be used as a molecular marker for diagnosing bladder cancer and judging prognosis, and as a new target for treating bladder cancer.

The invention provides an inhibitor of a heat shock factor 1 (HSF1) and an application of the inhibitor, particularly a compound as shown in a formula I or pharmaceutically-acceptable salt of the compound. The compound has excellent HSF1 restraining activity and tumor resisting effects. The invention further provides a medical composition containing the compound and an application of the medical composition in the respect of restraining HSF1.

The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

The invention discloses sgRNA for up-regulating non-coding RNA expression in a human DLK1-DIO3 imprinted domain, a recombinant plasmid and a cell line. The sgRNA sequence is shown as SEQ ID NO. 1, andspecifically as 5'-TTTATATGGAGGCGCAGAAG-3'; the method comprises the steps of: synthesizing a nucleic acid fragment of a sgRNA sequence and inserting into a multiple cloning site of the MS2-P65-HSF1expression plasmid vector and transforming, and selecting a monoclonal strain, extracting the recombinant plasmid of MS2-P65-HSF1-sgRNA-DLK1-DIO3, and transfecting the recombinant plasmid to the target cell line which is pre-transfected with dCAS9-VP64 plasmid to obtain the cell strain for up-regulating non-coding RNA expression in the DLK1-DIO3 imprinted domain. The application can rapidly, easily and accurately up-regulate the expression of non-coding RNA on the DLK1-DIO3 imprinted domain of the cell strain.

The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

The invention discloses a stepped fine adjustment method for the in-situ over-expression of a long-chain non-coding RNA-LINC00842. According to the method, LINC00842 specific sgRNA is used to positiondCas9 to a promoter region of an LINC00842 gene on a genome DNA, a transcription initiation complex is recruited in different degrees at a positioning site through the binding of MS2-P65-HSF1 with dCas9-fused VP64, and thereby the gradient adjustment of the in-situ over-expression of the LINC00842 gene is effectively realized. Moreover, a lentivirus system can integrate over-expression required elements (LINC00842-sgRNA, dCAS-VP64 and MS2-P65-HSF1) into a genome DNA of cells, the stable over-expression of LINC00842 in a cell strain is realized along with cell division and replication, and finally a cell strain series for stably over-expressing the LINC00842 gene with different amplitudes is obtained.